Skin Disorders Video 3: Boils

News
Article

A boil, painful and nasty: Is it a cyst? Is it a bug bite? Should you culture? Is it MRSA? How should you treat it? What if it recurs? Listen and learn.

Ted Rosen, MD, Professor of Dermatology at Baylor College of Medicine, offers bite-size pieces of useful clinical information on the “Top 10” skin disorders you see in your daily practice.

Segment 3: Boils

For more webinar videos, click here.

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Bacterial Vaginosis Recurrence Drops with Partner Treatment: Daily Dose / image credit: ©New Africa/AdobeStock

Bacterial Vaginosis Recurrence Drops with Partner Treatment: Daily Dose

Sydney Jennings
April 28th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Astrid Gast/AdobeStock

Elderly Atopic Dermatitis Cases Up 85% in the US Since 1990, New Study Shows

Sydney Jennings
April 23rd 2025
Article

New data also demonstrated mixed sex disparities in elderly atopic dermatitis prevalence.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

FDA Approves Dupilumab for Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Sydney Jennings
April 18th 2025
Article

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria

Emerging Therapies Show Potential for Hard-to-Treat Chronic Spontaneous Urticaria

Sydney Jennings
April 18th 2025
Article

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

© 2025 MJH Life Sciences

All rights reserved.